Dopamine Transporter imaging with Tc-99m TRODAT-1 SPECT in Parkinson’s disease and its correlation with clinical disease severity

Document Type : Original Article


1 Department of Nuclear Medicine and PET-CT, Apollo Hospitals, Chennai, Tamilnadu, India

2 Department of Nuclear Medicine and PET-CT, Apollo Hospitals, Chennai, Tamilnadu India

3 Department of Nuclear Medicine and PET-CT Apollo Hospitals, Chennai, Tamilnadu, India

4 Department of Nuclear Medicine and PET-CT Apollo Hospitals, Chennai, Tamilnadu India


Objective(s): To evaluate the role of Tc-99m TRODAT-1 Single Photon Emission Computed Tomography (SPECT) in Parkinson’s Disease (PD) by assessing the correlation of clinical disease severity, disease duration and age at onset of disease with specific uptake ratio of Tc-99m TRODAT-1 in striatum.
Methods: The study included 63 patients in age range of 40-72 years with clinical diagnosis of PD and nine controls. Clinical history of patients was obtained regarding age at onset of disease and disease duration. Disease severity in each patient was assessed using H and Y stage and UPDRS. Tc-99m TRODAT-1 SPECT was performed and specific uptake ratios were calculated for six regions in bilateral striata, caudate nuclei and putamina. Difference in specific uptake ratios between different stages of disease was analyzed for statistical significance. Specific uptake ratios were correlated with UPDRS, motor score of UPDRS, duration of disease and age at onset of disease using Pearson’s correlation co-efficient.
Results: Median specific uptake ratio was found to be least in contralateral putamen for all H and Y stages. There was a statistically significant difference between specific uptake ratios of controls vs stage 1, stage 1 vs 2, 1 vs 3, 1 vs 4, and 2 vs 4 for all 6 regions. The difference in uptake ratio between 3 and 4 H and Y stages was significant only for contralateral
regions. There was no significant difference in uptake ratio between 2 and 3 H and Y stages. The uptake ratios showed a strong negative correlation with UPDRS and motor score, a weak negative correlation with duration of disease and no significant correlation with age at onset of disease.
Conclusion: We conclude that Tc-99m TRODAT-1 SPECT can be used to assess the disease severity in PD patients.


Main Subjects

1. World Health Organization. Neurological disorders: public health challenges. Switzerland: World Health Organization; 2016.
2. Geng Y, Shi GH, Jiang Y, Xu LX, Hu XY, Shao YQ. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson’s disease. J Zhejiang Univ Sci B. 2005;6(1):22-7.
3. Wang L, Zhang Q, Li H, Zhang H. SPECT molecular imaging in Parkinson’s disease. J Biomed Biotechno. 2012;2012:1-16.
4. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81(1):5-12.
5. Park E. A new era of clinical dopamine transporter imaging using 123I-FP-CIT. J Nucl Med Technol. 2010;40(4):222-8.
6. Van Laere K, Casteels C, De Ceuninck L, Vanbilloen B, Maes A, Mortelmans L et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med. 2006;47(3):384-92.
7. Chou KL, Hurtig HI, Stern MB, Colcher A, Ravina B, Newberg A, et al. Diagnostic accuracy of [99mTc] TRODAT-1 SPECT imaging in early Parkinson’s disease. Parkinsonism Relat Disord. 2004;10(6):375-9.
8. Weng YH, Yen TC, Chen MC, Kao PF, Tzen KY, Chen RS, et al. Sensitivity and specificity of 99mTcTRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson’s disease from healthy subjects. J Nucl Med. 2004;45(3):393-401.
9. Spiegel J, Mollers MO, Jost WH, Fuss G, Samnick S, Dillmann U, et al. FP-CIT and MIBG scintigraphy in early Parkinson’s disease. Mov Disord. 2005;20(5):552-61.
10. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N- {omega}-fluoropropyl-2{beta}-carbomethoxy- 3{beta}-(4-Iodophenyl) Tropane SPECT in healthy controls and early-stage, drug-naive Parkinson’s disease. J Nucl Med. 1998;39(7):1143-8.
11. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15(4):692-8.
12. Tatsch K, Poepperl G. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. J Nucl Med. 2013;54(8):1331-8.
13. Bor-Seng-Shu E, Felicio AC, Braga-Neto P, Batista IR, Paiva WS, de Andrade DC, et al. Dopamine transporter imaging using 99mTc-TRODAT-1 SPECT in Parkinson’s disease. Med Sci Monit. 2014;20:1413-8.
14. Wu H, Lou C, Huang Z, Shi G. SPECT imaging of dopamine transporters with (99m)Tc-TRODAT-1 in major depression and Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2011;23(1):63-7.
15. Yin TK, Lee BF, Yang YK, Chiu NT. Differences of various region-of-interest methods for measuring dopamine transporter availability using 99mTcTRODAT-1 SPECT. Sci World J. 2014;2014:837439.
16. Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson’s disease with 99mTc-TRODAT-1 imaging. J Nucl Med. 2001;42(9):1303-8.
17. Eskandar EN. Hoehn and Yahr staging of Parkinson’s disease, Unified Parkinson disease Rating Scale (UPDRS), and Schwab and England activities of daily living. Available at: URL: http://neurosurgery.mgh. /functional/ pdstages.htm; Accessed 3 April 2016.
18. Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. 123I FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62(2):133-40.
19. Van Laere K, De Ceuninck L, Dom R, Van den Eynden J, Vanbilloen H, Cleynhens J, et al. Dopamine transporter SPECT using fast kinetic ligands: 123I-FP-β-CIT versus 99mTc-TRODAT-1. Eur J Nucl Med Mol Imaging. 2004;31(5):1119-27.
20. Lu CS, Weng YH, Chen MC, Chen RS, Tzen KY, Wey SP, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med. 2004;45(1):49-55.
21. Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson’s disease. J Nucl Med. 2004;45(2):207-13.